A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy

Yuichi Kakudo, Takashi Yoshioka, Santaro Noguchi, Masahito Hanada, Kazunori Otsuka, Masato Sakayori, Natsuko Chiba, Hiroyuki Shibata, Shunsuke Kato, Hideki Shimodaira, Hisatsugu Ohori, Shin Takahashi, Masanobu Takahashi, Gengo Yamaura, Katsuhiro Yasuda, Chikashi Ishioka

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

A 44-year-old man had a tumor in the lower thoracic esophagus at a health check, and was initially diagnosed as an undifferentiated carcinoma of the esophagus by the esophago-gastric endoscope. Although curative chemoradiotherapy was scheduled after the diagnosis, the interim evaluation revealed that the tumor was malignant melanoma of the esophagus with right renal metastasis. Since then, CVD (cisplatin, vindesine and dacarbazine) therapy, palliative radiotherapy and DAC-Tam (dacarbazine, nimustine, cisplatin and tamoxifen) therapy were carried out, but all of them proved ineffective, and multiple newly metastatic lesions appeared in liver and lymph nodes. Oral intake was impossible because of progressing stricture of the esophagus. As a fourth-line therapy, weekly paclitaxel therapy was started, and his oral intake was improved after the second course. He received the therapy as an outpatient for four months. After the third course, tumor lesions were evaluated as a partial response by CT. Consequently, five courses of the therapy were performed with modest adverse effects. Weekly paclitaxel therapy was reasonably safe as reported in other reports and considered to be a promising regimen for malignant melanoma of the esophagus.

Original languageEnglish
Pages (from-to)969-972
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Issue number7
Publication statusPublished - 2006 Jul

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy'. Together they form a unique fingerprint.

Cite this